ALNEV Share Price Performance
Recent ALNEV News & Updates
No updates
Neovacs S.A. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -69.06
- Gross Margin
- -638.26%
- Net Profit Margin
- -7,585.07%
- Debt/Equity Ratio
- 1.3%
Neovacs S.A. Competitors
About ALNEV
- Founded
- 1993
- Employees
- 20
- CEO
- WebsiteView website
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
French Market Performance
- 7 Days: -3.9%
- 3 Months: -3.5%
- 1 Year: 2.8%
- Year to Date: 0.7%
Over the last 7 days, the market has dropped 3.9%, driven by a decline of 7.9% in the Consumer Discretionary sector. Overall the market has been flat in the last year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading